The Technical Analyst
Select Language :
Epizyme Inc [EPZM]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Epizyme Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Epizyme Inc is listed at the  Exchange

0.00% $1.470

America/New_York / 31 des 1970 @ 19:00


RATING 2022-08-12
B-
Neutral
RATINGS
Rating CashFlow: Strong Buy
Return On Equity: Strong Buy
Return On Asset: Sell
DE: Strong Sell
P/E: Sell
Price To Book: Strong Sell
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -0.704 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.12x
Company: PE -0.704 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.421 - 1.519

( +/- 3.33%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-08-12 Giordano Michael F Sell 8 994 Common Stock, par value $0.0001
2022-08-12 Goldfischer Carl Sell 13 060 Common Stock, par value $0.0001
2022-08-12 Goldfischer Carl Sell 8 994 Common Stock, par value $0.0001
2022-08-12 Goldfischer Carl Sell 3 380 951 Common Stock, par value $0.0001
2022-08-12 Conroy Kevin T Sell 53 324 Common Stock, par value $0.0001
INSIDER POWER
-86.89
Last 98 transactions
Buy: 31 679 726 | Sell: 42 571 145

Forecast: 01:40 - $1.344

Live Trading Signals (every 1 min)

SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.470 (0.00% )
Volume 0 mill
Avg. Vol. 4.18 mill
% of Avg. Vol 0 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Epizyme Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Epizyme Inc

RSI

Intraday RSI14 chart for Epizyme Inc

Last 10 Buy & Sell Signals For EPZM

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Epizyme Inc

EPZM

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc..

Last 10 Buy Signals

Date Signal @
PYPLMar 28 - 13:02$67.14
MBLYMar 28 - 13:0233.21
GLMUSDMar 28 - 13:02$0.592
WIXMar 28 - 13:01$139.49
TGTXMar 28 - 13:01$15.38
USIGMar 28 - 13:01$50.81
TXGMar 28 - 13:01$38.11
TTDMar 28 - 13:01$87.81
MPWRMar 28 - 13:01$675.22
ASNDMar 28 - 13:01$146.65

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.